By Michael Fitzhugh
Positive new pivotal data has shown that ZX-008, Zogenix Inc.’s re-imagining of a key component of the ill-fated obesity drug Fen-Phen, can significantly reduce seizure frequency in children with the rare genetic epilepsy, Dravet syndrome. The result kept Zogenix on track to seek U.S. and European approvals for the drug in the second half of 2018 and fueled investor enthusiasm for the company’s shares (NASDAQ:ZGNX), which climbed 172.2 percent on Friday to close at $35.05.
Zogenix president and CEO Steve Farr said that the results represent “one of the most significant milestones in our company’s history” and disclosed that a second pivotal trial, known as study 1504, is near full enrollment, laying the groundwork for a top-line report in the first half of 2018.
Though the exact number of children affected by Dravet is unknown, reports